ZenaTech's Defense Expansion Inches Forward with Rattler Medical MOU, but Valuation and Cash Burn Remain Unchanged

What happened

ZenaTech announced that its ZenaDrone subsidiary signed a memorandum of understanding with Rattler Medical to develop a drone-based battlefield blood delivery system. The MOU is exploratory, lacking binding commitments, revenues, or defined timelines. ZenaTech's fundamentals remain deeply negative with Q3 2025 free cash flow of -$8.36 million and operating margins below -100%. The stock trades at approximately 9x run-rate revenue with negative tangible book value and is rated POTENTIAL SELL in our latest deep value report. While the defense optionality narrative gains another data point, it does not alter the core risk of dilution and cash burn.

Implication

The MOU with Rattler Medical adds another speculative defense initiative to ZenaTech's story but no near-term financial impact. It does not address the company's negative unit economics, high cash burn, or need for external capital. Until ZenaTech converts these announcements into multi-year, funded defense contracts with visible revenue, they remain promotional in nature. Investors should continue to monitor key checkpoints: revenue growth above 50% YoY, margin improvement, and progress toward the 25-location DaaS goal. Given the current valuation and balance sheet strain, the stock still offers no margin of safety and is best avoided or reduced on strength.

Thesis delta

The announcement represents incremental positive optionality for the defense narrative but does not alter our thesis. Our base case remains that ZenaTech is a cash-burning, acquisition-driven company with unproven economics trading at speculative multiples. We maintain a POTENTIAL SELL rating with conviction 4, as the MOU adds no revenue, cash flow, or balance sheet improvement and the risk of value-destructive dilution persists.